ISG Technologies continues to move forward from its proxy fight of a year ago. The Mississauga, Ontario-based medical imaging software developer reported an 8% increase in revenue for its 1998 fiscal first quarter, bringing sales to a company record for
ISG Technologies continues to move forward from its proxy fight of a year ago. The Mississauga, Ontario-based medical imaging software developer reported an 8% increase in revenue for its 1998 fiscal first quarter, bringing sales to a company record for the period.
ISG reported revenues of $5.8 million (U.S.) for the period (end-September), compared with $5.4 million in the first quarter of 1997. Net income was $6400, compared with a net loss of $780,000 in the same period last year. No extraordinary charges were reported during the quarter. The company increased its backlog during the period by more than $6.3 million, representing multiyear agreements for licensed software and contract engineering work, according to the firm.
While revenues from the company's image-guided surgery line were down significantly, substantial gains in sales of ISG's Viewing and Reading Station (VRS) PACS software offset the loss, resulting in overall flat revenues of $2.8 million for the company's licensed software efforts. Contract R&D revenues rose 48% to $2.8 million.
The company also reported favorable developments in its IAP medical imaging console software business. In other quarterly developments, ISG released a Windows NT version of its VRS product line. Previously, VRS was based exclusively on the Unix operating system.
GE HealthCare Debuts AI-Powered Cardiac CT Device at ACC Conference
April 1st 2025Featuring enhanced low-dose image quality with motion-free images, the Revolution Vibe CT system reportedly facilitates improved diagnostic clarity for patients with conditions ranging from in-stent restenosis to atrial fibrillation.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.